Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
5xFAD mouse model
Alzheimer’s disease
Amyloid beta
Isoaspartate
Passive immunotherapy
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
14 11 2020
14 11 2020
Historique:
received:
07
05
2020
accepted:
29
10
2020
entrez:
15
11
2020
pubmed:
16
11
2020
medline:
25
6
2021
Statut:
epublish
Résumé
Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer's disease (AD) trials, but successful translation to late clinics has failed so far. Compelling evidence suggests that post-translationally modified Aβ peptides might play a decisive role in onset and progression of AD and first clinical trials targeting such Aβ variants have been initiated. Modified Aβ represents a small fraction of deposited material in plaques compared to pan-Aβ epitopes, opening up pathways for tailored approaches of immunotherapy. Here, we generated the first monoclonal antibodies that recognize L-isoaspartate-modified Aβ (isoD7-Aβ) and tested a lead antibody molecule in 5xFAD mice. This work comprises a combination of chemical and biochemical techniques as well as behavioral analyses. Aβ peptides, containing L-isoaspartate at position 7, were chemically synthesized and used for immunization of mice and antibody screening methods. Biochemical methods included anti-isoD7-Aβ monoclonal antibody characterization by surface plasmon resonance, immunohistochemical staining of human and transgenic mouse brain, and the development and application of isoD7-Aβ ELISA as well as different non-modified Aβ ELISA. For antibody treatment studies, 12 mg/kg anti-isoD7-Aβ antibody K11_IgG2a was applied intraperitoneally to 5xFAD mice for 38 weeks. Treatment controls implemented were IgG2a isotype as negative and 3D6_IgG2a, the parent molecule of bapineuzumab, as positive control antibodies. Behavioral studies included elevated plus maze, pole test, and Morris water maze. Our advanced antibody K11 showed a K The present study demonstrates, for the first time, that the antibody-mediated targeting of isoD7-modified Aβ peptides leads to attenuation of AD-like amyloid pathology. In conjunction with previously published data on antibodies directed against pGlu-modified Aβ, the results highlight the crucial role of modified Aβ peptides in AD pathophysiology. Hence, the results also underscore the therapeutic potential of targeting modified amyloid species for defining tailored approaches in AD therapy.
Sections du résumé
BACKGROUND
Amyloid β (Aβ)-directed immunotherapy has shown promising results in preclinical and early clinical Alzheimer's disease (AD) trials, but successful translation to late clinics has failed so far. Compelling evidence suggests that post-translationally modified Aβ peptides might play a decisive role in onset and progression of AD and first clinical trials targeting such Aβ variants have been initiated. Modified Aβ represents a small fraction of deposited material in plaques compared to pan-Aβ epitopes, opening up pathways for tailored approaches of immunotherapy. Here, we generated the first monoclonal antibodies that recognize L-isoaspartate-modified Aβ (isoD7-Aβ) and tested a lead antibody molecule in 5xFAD mice.
METHODS
This work comprises a combination of chemical and biochemical techniques as well as behavioral analyses. Aβ peptides, containing L-isoaspartate at position 7, were chemically synthesized and used for immunization of mice and antibody screening methods. Biochemical methods included anti-isoD7-Aβ monoclonal antibody characterization by surface plasmon resonance, immunohistochemical staining of human and transgenic mouse brain, and the development and application of isoD7-Aβ ELISA as well as different non-modified Aβ ELISA. For antibody treatment studies, 12 mg/kg anti-isoD7-Aβ antibody K11_IgG2a was applied intraperitoneally to 5xFAD mice for 38 weeks. Treatment controls implemented were IgG2a isotype as negative and 3D6_IgG2a, the parent molecule of bapineuzumab, as positive control antibodies. Behavioral studies included elevated plus maze, pole test, and Morris water maze.
RESULTS
Our advanced antibody K11 showed a K
CONCLUSIONS
The present study demonstrates, for the first time, that the antibody-mediated targeting of isoD7-modified Aβ peptides leads to attenuation of AD-like amyloid pathology. In conjunction with previously published data on antibodies directed against pGlu-modified Aβ, the results highlight the crucial role of modified Aβ peptides in AD pathophysiology. Hence, the results also underscore the therapeutic potential of targeting modified amyloid species for defining tailored approaches in AD therapy.
Identifiants
pubmed: 33189132
doi: 10.1186/s13195-020-00719-x
pii: 10.1186/s13195-020-00719-x
pmc: PMC7666770
doi:
Substances chimiques
Amyloid beta-Peptides
0
Amyloid beta-Protein Precursor
0
Isoaspartic Acid
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
149Références
Angew Chem Int Ed Engl. 2016 Apr 11;55(16):5081-4
pubmed: 26970534
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Alzheimers Res Ther. 2016 Jul 30;8(1):23
pubmed: 27473681
Am J Pathol. 2004 Sep;165(3):987-95
pubmed: 15331422
J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1039-42
pubmed: 15201367
Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8
pubmed: 12566568
Neuron. 2011 Sep 8;71(5):833-44
pubmed: 21903077
J Neurosci. 2006 Oct 4;26(40):10129-40
pubmed: 17021169
Curr Top Cell Regul. 1974;8(0):247-95
pubmed: 4371091
J Biol Chem. 1987 Jan 15;262(2):785-94
pubmed: 3805008
Biochemistry. 2009 Jul 28;48(29):7072-8
pubmed: 19518051
J Neurosci Res. 2002 Nov 1;70(3):451-61
pubmed: 12391606
Biophys J. 2010 Nov 17;99(10):L84-6
pubmed: 21081056
Bioorg Med Chem Lett. 1999 Apr 5;9(7):953-6
pubmed: 10230618
Neurobiol Aging. 2015 Dec;36(12):3187-3199
pubmed: 26453001
Learn Mem. 2008 Dec 30;16(1):38-45
pubmed: 19117915
J Biol Chem. 1993 Feb 15;268(5):3072-83
pubmed: 8428986
EMBO J. 2011 Jun 1;30(11):2255-65
pubmed: 21527912
Acta Neuropathol. 2015 Oct;130(4):487-99
pubmed: 26363791
J Pharm Biomed Anal. 2000 Jan;21(6):1129-36
pubmed: 10708396
Biochim Biophys Acta. 1998 Apr 28;1406(3):291-8
pubmed: 9630681
Neurology. 1991 Apr;41(4):479-86
pubmed: 2011243
Rapid Commun Mass Spectrom. 2008;22(2):231-9
pubmed: 18085519
Am J Pathol. 2013 Aug;183(2):369-81
pubmed: 23747948
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Neurotox Res. 2013 Oct;24(3):370-6
pubmed: 23670398
Cell Mol Life Sci. 2003 Jul;60(7):1281-95
pubmed: 12943218
Neurobiol Aging. 1997 Jul-Aug;18(4 Suppl):S1-2
pubmed: 9330978
Amino Acids. 2013 Apr;44(4):1205-14
pubmed: 23344882
Nat Med. 2000 Aug;6(8):916-9
pubmed: 10932230
Nat Commun. 2016 Apr 13;7:11359
pubmed: 27072999
Chembiochem. 2008 Jul 2;9(10):1564-7
pubmed: 18506864
Science. 2017 Oct 6;358(6359):116-119
pubmed: 28882996
Biochem Biophys Res Commun. 1984 Aug 16;122(3):1131-5
pubmed: 6236805
Biol Pharm Bull. 2005 Sep;28(9):1590-6
pubmed: 16141521
Cell Death Dis. 2013 Nov 28;4:e939
pubmed: 24287700
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5
pubmed: 11438712
J Biol Chem. 1989 Apr 15;264(11):6164-70
pubmed: 2703484
Brain Res. 1989 Jan 16;477(1-2):90-9
pubmed: 2495152
Exp Neurol. 1999 Jun;157(2):277-88
pubmed: 10364440
Arch Biochem Biophys. 2000 Sep 15;381(2):225-34
pubmed: 11032409
Ann Neurol. 2011 May;69(5):819-30
pubmed: 21472769
Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):944-9
pubmed: 11158575
Neuron. 2012 Dec 6;76(5):908-20
pubmed: 23217740
EMBO Rep. 2017 Jun;18(6):962-981
pubmed: 28420656
Alzheimers Res Ther. 2014 May 26;6(3):28
pubmed: 25031638
Nature. 1992 Jun 11;357(6378):500-3
pubmed: 1608449
Cold Spring Harb Perspect Med. 2012 Jun;2(6):a006262
pubmed: 22675658
Proc Natl Acad Sci U S A. 1970 Jul;66(3):753-7
pubmed: 5269237
Biochem Biophys Res Commun. 2013 Nov 15;441(2):493-8
pubmed: 24383085
Neurotox Res. 2016 May;29(4):551-7
pubmed: 26842600
Arch Neurol. 2002 Nov;59(11):1764-7
pubmed: 12433264
Neurodegener Dis. 2012;10(1-4):265-70
pubmed: 22343072